Table 1.

Reported cases of locally advanced and metastatic non-melanoma skin cancers treated with ipilimumab.

Number of Patients	Patient Data (Sex, Age)	Diagnosis	Ipilimumab Regimen	Outcome	Additional Information	Ref.
1	M, 72 y	m-cSCC	3 mg/kg ipilimumab IV every 3 weeks	PR	Concurrent melanoma	Day et al., 2017 [28]
1	M, in his 60 s	la-BCC	3 mg/kg ipilimumab IV every 3 weeks	PR	Concurrent melanoma	Mohan et al., 2016 [29]
5	4 M, 1 F; age: 50–81 y	m-MCCs	3 mg/kg ipilimumab IV every 3 weeks	2 CR; 2 SD; 1 PD	/	Winkler et al., 2017 [31]
5	4 M, 1 F; age: 57–70 y	m-MCCs	3 mg/kg ipilimumab IV + nivolumab 1 mg/kg IV OR 1 mg/kg ipilimumab IV + nivolumab 3 mg/kg IV	1 CR; 2 PR	Avelumab refractory disease	Glutsch et al., 2021 [36]
1	M, 65 y	m-MCC	1 mg/kg ipilimumab IV every 6 weeks + 240 mg nivolumab IV. every 2 weeks	CR	Avelumab refractory disease	Khaddour et al., 2021 [37]

Note: Abbreviations: M (male); F (female); y (years); m-cSCC (metastatic cutaneous squamous cell carcinoma); la-BCC (locally advanced basal cell carcinoma); m-MCC (metastatic Merkel cell carcinoma); IV (intravenously); CR (complete response); PR (partial response); SD (stable disease); PD (progressive disease).